期刊文献+

孕妇血清中HBVDNA及IFN-γ、IL-4、IL-6与HBV宫内感染关系的研究 被引量:6

在线阅读 下载PDF
导出
摘要 目的:研究孕妇血清中乙型肝炎病毒DNA(HBVDNA)及干扰素-γ(IFN-γ)、白细胞介素-4(IL-4)、白细胞介素-6(IL-6)在HBV宫内感染中的作用及相关性。方法:采用双抗夹心酶联免疫吸附法(DAS-ELISA)检测研究组80例乙型肝炎病毒表面抗原(HBsAg)或(和)HBeAg阳性和对照组20例正常妊娠孕妇的外周静脉血及其新生儿外周静脉血血清中乙型肝炎病毒5项指标(HBVM)、IFN-γ、IL-4、IL-6水平,采用荧光定量PCR法行HBVDNA检测。结果:HBVDNA阳性的宫内感染率是25.81%,HBVDNA阴性的宫内感染率是6.12%。HBeAg阳性、阴性孕妇的HBVDNA阳性率及宫内感染率比较,差异均有统计学意义(P<0.01)。与对照组比较,孕28周时HBsAg阳性孕妇其血IFN-γ水平降低,IL-4、IL-6水平升高,差异有统计学意义(P<0.05)。使用乙型免疫球蛋白(HBIG)后,HBsAg阳性孕妇的IFN-γ水平上升、IL-4和IL6水平下降,治疗前后差异有统计学意义(P<0.05)。上述3组孕妇血清中IL-4与IL-6水平均呈正相关(P<0.01);IFN-γ与IL-4呈负相关(P<0.01);IFN-γ与IL-6亦呈负相关(P<0.01)。结论:估计HBV宫内感染危险性时,HBVDNA较HBeAg更可靠,产前应用HBIG可改善孕妇体内TH1/TH2功能失衡,使IFN-γ上升,IL-4、IL-6下降,IFN-γ、IL-4、IL-6在阻断HBV宫内感染的发病机制中有一定作用。
出处 《广西医科大学学报》 CAS 北大核心 2007年第2期233-235,共3页 Journal of Guangxi Medical University
基金 广西科学基金资助项目(No.0339027)
  • 相关文献

参考文献2

二级参考文献27

  • 1AZeuzem S, Carreno V. Interleukin-12 in the treatment of chronic hepatitis B and C. Antiviral Res 2001; 52:181-188.
  • 2Bradham CA, Plumpe J, Manns MP, Brenner DA, Tautwein C. Mechanisms of hepatic toxicity I. TNF-induced liver injury.Am J Physiol 1998; 275:387-392.
  • 3Schlaak JF, Tully G, L6hr HF, Gerken G. HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro-and anti-inflammatory cytokines. Clin Exp Immunol 1999; 115:508-514.
  • 4Jiang R, Feng X, Guo Y, Lu Q, Hou J, Luo K, Fu N. T helper cells in patients with chronic hepatitis B virus infection. Chin Med J 2002, 115: 422-424.
  • 5Kobayashi K, Ishii M, Igarashi T, Satoh T, Miyazaki Y, Yajima Y, Ukai K, Suzuki H, Kanno A, Ueno Y, Miura T, Toyota T.Profiles of cytokines produced by CD4-positive T lymphocytes stimulated by anti-CD3 antibody in patients with chronic hepatitis C. J Gastroenterol 1998; 33:500-507.
  • 6Atsukawa K,Saito H, Tsukada N, Akiba Y, Toda K, Kumagai N, Ohishi T, Kamegaya Y, Ishii H. Thl and Th2 cytokines differentially regulate the transformation of Kupffer cells into multinucleated giant cells but similarly enhance the Kupffer cell-induced hepatic stellate cell proliferation. Hepatology Res 2001; 20:193-206.
  • 7Hirohashi S, Ishak KG, Kojiro M, Wangless IR, Theise ND,Tsukuma H. Hepatocellular Carcinoma. Hamilton SR,Aaltonen LA. Pathology and Genetics Tumours of the Digestive System. First edition. Lyon: IARC 2000,159-172.
  • 8Schiirch W, Gurley AM, Roth SI. Myofibroblast. Sternberg SS. Histology for Pathologists. Second edition. Philadelphia:Lippincott Raven 1997,129-166.
  • 9Kweon Y, Goodman ZD, Diestang JL, Schiff ER, Brown NA,Burkhardt E. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol 2001; 35:749-755.
  • 10Neuman MG, Benhamou JP, Bourliere M, Ibrahim A,Malkiewicz I, Asselah T, Martinot-Peignoux M, Shear NH,Katz GG, Akremi R, Benali S, Boyer N, Lecomte L, Le Breton V, Le Guludec G, Marcellin P. Serum tumor necrosis factor-α and transforming growth factor-β levels in chronic hepatitis C patients are immunomodulated by therapy. Cytokine 2002;17:108-117.

共引文献54

同被引文献94

引证文献6

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部